Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2018 Nov 19. pii: S1569-1993(18)30914-7. doi: 10.1016/j.jcf.2018.10.015. [Epub ahead of print]

2.

NEBNext Direct: A Novel, Rapid, Hybridization-Based Approach for the Capture and Library Conversion of Genomic Regions of Interest.

Emerman AB, Bowman SK, Barry A, Henig N, Patel KM, Gardner AF, Hendrickson CL.

Curr Protoc Mol Biol. 2017 Jul 5;119:7.30.1-7.30.24. doi: 10.1002/cpmb.39.

PMID:
28678441
3.

Genetic medicines for CF: Hype versus reality.

Alton EW, Boyd AC, Davies JC, Gill DR, Griesenbach U, Harrison PT, Henig N, Higgins T, Hyde SC, Innes JA, Korman MS.

Pediatr Pulmonol. 2016 Oct;51(S44):S5-S17. doi: 10.1002/ppul.23543. Review.

4.

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.

Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG.

Eur Respir J. 2015 Nov;46(5):1370-7. doi: 10.1183/13993003.01537-2014. Epub 2015 Aug 6.

5.

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.

Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, Lipuma JJ.

J Cyst Fibros. 2014 May;13(3):296-305. doi: 10.1016/j.jcf.2013.08.011. Epub 2013 Oct 28.

6.

Advancing clinical trial design in pulmonary hypertension.

Grieve AP, Chow SC, Curram J, Dawe S, Harnisch LO, Henig NR, Hung HM, Ivy DD, Kawut SM, Rahbar MH, Xiao S, Wilkins MR.

Pulm Circ. 2013 Jan;3(1):217-25. doi: 10.4103/2045-8932.109933.

7.

Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells.

Henig N, Avidan N, Mandel I, Staun-Ram E, Ginzburg E, Paperna T, Pinter RY, Miller A.

PLoS One. 2013 Apr 23;8(4):e62366. doi: 10.1371/journal.pone.0062366. Print 2013.

8.

Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.

Anderson GG, Kenney TF, Macleod DL, Henig NR, O'Toole GA.

Pathog Dis. 2013 Feb;67(1):39-45. doi: 10.1111/2049-632X.12015. Epub 2013 Jan 10.

9.

Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.

Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, Anglen C, Kohan DE.

Am J Cardiol. 2012 Nov 1;110(9):1373-7. doi: 10.1016/j.amjcard.2012.06.040. Epub 2012 Aug 2.

10.

Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.

Ben-Yehuda O, Pizzuti D, Brown A, Littman M, Gillies H, Henig N, Peschel T.

J Am Coll Cardiol. 2012 Jul 3;60(1):80-1. doi: 10.1016/j.jacc.2012.03.025. Epub 2012 May 9. No abstract available.

11.

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.

Elborn JS, Henig NR.

Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Review.

PMID:
20426707
12.
13.
14.

Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.

Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, Yee JY, Kotloff RM, Lipson DA, Bunin GR.

Am J Respir Crit Care Med. 2006 Mar 15;173(6):659-66. Epub 2005 Dec 30.

15.

Ethical issues in the long-term management of progressive degenerative neuromuscular diseases.

Vaszar LT, Weinacker AB, Henig NR, Raffin TA.

Semin Respir Crit Care Med. 2002 Jun;23(3):307-14.

PMID:
16088623
16.

Lung transplantation: a decade of experience.

Moffatt SD, Demers P, Robbins RC, Doyle R, Wienacker A, Henig N, Theodore J, Reitz BA, Whyte RI.

J Heart Lung Transplant. 2005 Feb;24(2):145-51.

PMID:
15701428
17.

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

OrdoƱez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML.

Am J Respir Crit Care Med. 2003 Dec 15;168(12):1471-5. Epub 2003 Sep 11.

PMID:
12969869
18.

Sinus disease in cystic fibrosis.

Mak GK, Henig NR.

Clin Rev Allergy Immunol. 2001 Aug;21(1):51-63. Review. No abstract available.

PMID:
11471341
19.

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis.

Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML.

Thorax. 2001 Apr;56(4):306-11.

20.

Conflict over communication and unprofessional staff behavior: a common source of dissatisfaction during the withdrawal of care?

McGee DC, Shigemitsu H, Henig NR, Raffin TA.

Crit Care Med. 2001 Jan;29(1):217-9. No abstract available.

PMID:
11200243
21.

Mechanisms of hypoxemia.

Henig NR, Pierson DJ.

Respir Care Clin N Am. 2000 Dec;6(4):501-21. Review.

PMID:
11172576
22.

Biomedical ethics and the withdrawal of advanced life support.

Henig NR, Faul JL, Raffin TA.

Annu Rev Med. 2001;52:79-92.

PMID:
11160769
23.

Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses.

Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr.

Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):523-7.

PMID:
10934081
24.

A hypertrophied bronchial circulatory system may participate in gas exchange.

Henig NR, Glenny RW, Aitken ML.

Lancet. 1998 Jan 10;351(9096):113. No abstract available.

PMID:
9439503
25.

Update on clinical trials of cystic fibrosis.

Henig NR, Aitken ML.

Curr Opin Pulm Med. 1997 Nov;3(6):404-9. Review.

PMID:
9391758

Supplemental Content

Support Center